glp-1 lawsuit 2025 Lawsuits claiming Ozempic, other GLP-1s led to blindness become second mass litigation over the drugs GLP-1 Drugs: 2025 Pulse Survey

Supplied for research use only not for human or veterinary use

But affordability should not lead to casual use

Safety, Side Effects, and What Evidence Actually Shows Injectable and oral GLP-1 medications carry well-documented side effect profiles from thousands of clinical trial participants: nausea, vomiting, constipation, and potential pancreatitis risk in susceptible individuals

In the Phase 2 obesity trial, retatrutide 12 mg produced approximately 24.2% mean weight loss at 48 weeks ( Jastreboff et al., NEJM 2023 ), and the Phase 2 type 2 diabetes trial showed strong HbA1c and weight reductions ( Rosenstock et al., Lancet 2023 )

Knowing when to begin is crucial for achieving natural and beautiful results when seeking to smooth wrinkles, enhance facial contours, or restore lost volume